Analysis of Systemic Endothelin-1, Matrix Metalloproteinase-9, Macrophage Chemoattractant Protein-1, and High-Sensitivity C-Reactive Protein in Normal-Tension Glaucoma

REFERENCES

• Van Buskirk EM, Cioffi GA. Glaucomatous optic neuropathy. Am J Ophthalmol 1992;113:447–452.
   PubMed Web of Science ®Google Scholar
• Allingham RR, Damji KF, Freedman S et al. Shields textbook of glaucoma. 6th edition. Philadelphia: LWW; 2011. pp xiii.
   Google Scholar
• Drance SM, Sweeney VP, Morgan RW et al. Studies of factors involved in the production of low tension glaucoma. Arch Ophthalmol 1973;89:457–465.
   PubMedGoogle Scholar
• Gasser P. Ocular vasospasm: a risk factor in the pathogenesis of low-tension glaucoma. Int Ophthalmol 1989;13:281–290.
   PubMedGoogle Scholar
• Rojanapongpun P, Drance SM. The response of blood flow velocity in the ophthalmic artery and blood flow of the finger to warm and cold stimuli in glaucomatous patients. Graefes Arch Clin Exp Ophthalmol 1993;231:375–377.
   PubMed Web of Science ®Google Scholar
• Kim CS, Seong GJ, Lee NH et al; Namil Study Group, Korean Glaucoma Society. Prevalence of primary open-angle glaucoma in central South Korea the Namil study. Ophthalmology 2011;118:1024–1030.
   PubMed Web of Science ®Google Scholar
• Sugiyama T, Moriya S, Oku H et al. Association of endothelin-1 with normal tension glaucoma: clinical and fundamental studies. Surv Ophthalmol 1995;39 Suppl 1:S49–S56.
   PubMed Web of Science ®Google Scholar
• Henry E, Newby DE, Webb DJ et al. Altered endothelin-1 vasoreactivity in patients with untreated normal-pressure glaucoma. Invest Ophthalmol Vis Sci 2006;47:2528–2532.
   PubMed Web of Science ®Google Scholar
• Conti P, DiGioacchino M. MCP-1 and RANTES are mediators of acute and chronic inflammation. Allergy Asthma Proc 2001;22:133–137.
   PubMed Web of Science ®Google Scholar
• Koyama Y, Baba A, Matsuda T. Production of monocyte chemoattractant protein-1 and cytokine-induced neutrophil chemoattractant-1 in rat brain is stimulated by intracerebroventricular administration of an endothelin ETB receptor agonist. Neuroreport 2007;18:1275–1279.
   PubMed Web of Science ®Google Scholar
• Shin WS, Szuba A, Rockson SG. The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis 2002;160:91–102.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Peters AM, Paleolog E et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:38–47.
   PubMed Web of Science ®Google Scholar
• O’Hayre M, Salanga CL, Handel TM et al. Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. Biochem J 2008;409:635–649.
   PubMed Web of Science ®Google Scholar
• Gourmala NG, Buttini M, Limonta S et al. Differential and time-dependent expression of monocyte chemoattractant protein-1 mRNA by astrocytes and macrophages in rat brain: effects of ischemia and peripheral lipopolysaccharide administration. J Neuroimmunol 1997;74:35–44.
   PubMed Web of Science ®Google Scholar
• Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165–2168.
   PubMed Web of Science ®Google Scholar
• Leibovitch I, Kurtz S, Kesler A et al. C-reactive protein levels in normal tension glaucoma. J Glaucoma 2005;14:384–386.
   PubMed Web of Science ®Google Scholar
• Su WW, Ho WJ, Cheng ST et al. Systemic high-sensitivity C-reactive protein levels in normal-tension glaucoma and primary open-angle glaucoma. J Glaucoma 2007;16:320–323.
   Google Scholar
• de Voogd S, Wolfs RC, Jansonius NM et al. Atherosclerosis, C-reactive protein, and risk for open-angle glaucoma: the Rotterdam study. Invest Ophthalmol Vis Sci 2006;47:3772–3776.
   PubMedGoogle Scholar
• Mozaffarieh M, Flammer J. Is there more to glaucoma treatment than lowering IOP? Surv Ophthalmol 2007;52 Suppl 2:S174–S179.
   Google Scholar
• Agapova OA, Ricard CS, Salvador-Silva M et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human optic nerve head astrocytes. Glia 2001;33:205–216.
   PubMed Web of Science ®Google Scholar
• Golubnitschaja O, Yeghiazaryan K, Liu R et al. Increased expression of matrix metalloproteinases in mononuclear blood cells of normal-tension glaucoma patients. J Glaucoma 2004;13:66–72.
   PubMed Web of Science ®Google Scholar
• Good TJ, Kahook MY. The role of endothelin in the pathophysiology of glaucoma. Expert Opin Ther Targets 2010;14:647–654.
   PubMed Web of Science ®Google Scholar
• Shields MB. Normal-tension glaucoma: is it different from primary open-angle glaucoma? Curr Opin Ophthalmol 2008;19:85–88.
   PubMed Web of Science ®Google Scholar
• Chen HY, Chang YC, Chen WC et al. Association between plasma endothelin-1 and severity of different types of glaucoma. J Glaucoma 2011;Sep 22.
   Google Scholar
• Grieshaber MC, Flammer J. Does the blood-brain barrier play a role in Glaucoma? Surv Ophthalmol 2007;52 Suppl 2:S115–S121.
   PubMedGoogle Scholar
• Nicolela MT, Ferrier SN, Morrison CA et al. Effects of cold-induced vasospasm in glaucoma: the role of endothelin-1. Invest Ophthalmol Vis Sci 2003;44:2565–2572.
   PubMed Web of Science ®Google Scholar
• Resch H, Garhofer G, Fuchsjäger-Mayrl G et al. Endothelial dysfunction in glaucoma. Acta Ophthalmol 2009;87:4–12.
   PubMed Web of Science ®Google Scholar
• Kunimatsu S, Mayama C, Tomidokoro A et al. Plasma endothelin-1 level in Japanese normal tension glaucoma patients. Curr Eye Res 2006;31:727–731.
   PubMed Web of Science ®Google Scholar
• Kaiser HJ, Flammer J, Wenk M et al. Endothelin-1 plasma levels in normal-tension glaucoma: abnormal response to postural changes. Graefes Arch Clin Exp Ophthalmol 1995;233:484–488.
   PubMed Web of Science ®Google Scholar
• Chen P, Shibata M, Zidovetzki R et al. Endothelin-1 and monocyte chemoattractant protein-1 modulation in ischemia and human brain-derived endothelial cell cultures. J Neuroimmunol 2001;116:62–73.
   PubMed Web of Science ®Google Scholar
• Nagasawa H, Kogure K. Correlation between cerebral blood flow and histologic changes in a new rat model of middle cerebral artery occlusion. Stroke 1989;20:1037–1043.
   PubMed Web of Science ®Google Scholar
• Kochanek PM, Hallenbeck JM. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 1992;23:1367–1379.
   PubMed Web of Science ®Google Scholar
• Pepys MB, Berger A. The renaissance of C reactive protein. BMJ 2001;322:4–5.
   Google Scholar
• Kirwan RP, Crean JK, Fenerty CH et al. Effect of cyclical mechanical stretch and exogenous transforming growth factor-beta1 on matrix metalloproteinase-2 activity in lamina cribrosa cells from the human optic nerve head. J Glaucoma 2004;13:327–334.
   PubMed Web of Science ®Google Scholar
• Grieshaber MC, Terhorst T, Flammer J. The pathogenesis of optic disc splinter haemorrhages: a new hypothesis. Acta Ophthalmol Scand 2006;84:62–68.
   PubMedGoogle Scholar
• Flammer J, Mozaffarieh M. What is the present pathogenetic concept of glaucomatous optic neuropathy? Surv Ophthalmol 2007;52 Suppl 2:S162–S173.
   PubMed Web of Science ®Google Scholar
• Chintala SK, Zhang X, Austin JS et al. Deficiency in matrix metalloproteinase gelatinase B (MMP-9) protects against retinal ganglion cell death after optic nerve ligation. J Biol Chem 2002;277:47461–47468.
   PubMed Web of Science ®Google Scholar
• He S, Prasanna G, Yorio T. Endothelin-1-mediated signaling in the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in astrocytes. Invest Ophthalmol Vis Sci 2007;48:3737–3745.
   PubMed Web of Science ®Google Scholar
• Collaborative NTG Study Group. Comparison of glaucomatous progression between untreated patients with NTG and patients with therapeutically reduced IOP. Am J Ophthalmol 1998;126:487–497.
   Google Scholar